Identification of microRNA profiles associated with refractory primary biliary cirrhosis

Sakamoto,Teppei; Morishita,Asahiro; Nomura,Takako; Tani,Joji; Miyoshi,Hisaaki; Yoneyama,Hirohiro; Iwama,Hisakazu; Himoto,Takashi; Masaki,Tsutomu

doi:10.3892/mmr.2016.5606

Identification of microRNA profiles associated with refractory primary biliary cirrhosis

Authors:
- Teppei Sakamoto
- Asahiro Morishita
- Takako Nomura
- Joji Tani
- Hisaaki Miyoshi
- Hirohiro Yoneyama
- Hisakazu Iwama
- Takashi Himoto
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, Miki‑cho, Kagawa 761‑0793, Japan, Life Science Research Center, Kagawa University Faculty of Medicine, Miki‑cho, Kagawa 761‑0793, Japan, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761‑0123, Japan
Published online on: August 9, 2016 https://doi.org/10.3892/mmr.2016.5606
Pages: 3350-3356

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that control the target gene translation by RNA interference; miRNAs are associated with cellular processes, including proliferation, differentiation, apoptosis, and cell survival. Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown etiology. One third of patients with PBC demonstrate suboptimal responses, which result in worse outcomes. It has been previously reported that miRNAs are involved in drug resistance, however, the association between miRNA expression levels and refractory PBC remains to be fully elucidated. In the present study, among the 20 patients with PBC treated with ursodeoxycholic acid or bezafibrate, 15 patients were classed as treatment‑effective, and 5 were classed as being treatment‑resistant. Using the miRNA array technique, miRNA profiles were identified for each group. A total of 35 miRNAs were significantly upregulated, and 23 were significantly downregulated in the treatment‑resistant group compared with the treatment‑effective group. In order to examine the association between the highly altered miRNAs and clinical features of the two groups, numerous parameters were analyzed. Elevated levels of direct bilirubin, aspartate transaminase (AST), and alanine transaminase (ALT) were identified to be associated with miRNA‑122 upregulation. AST, ALT, and γ guanosine triphosphate were additionally associated with miRNA‑378f upregulation. However, the reduction of miRNA‑4311 was associated with reduced levels of AST and ALT. miRNA‑4714‑3p was also negatively correlated with total bilirubin and lactate dehydrogenase. Therefore, identifying the miRNA profile was demonstrated to be a useful approach in the characterization of PBC development. It is suggested that highly altered miRNAs may be potential biomarkers for use in the development of treatment of patients with refractory PBC.

View Figures

View References

1	Morishita A and Masaki T: miRNA in hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
2	Suzuki H, Maruyama R, Yamamoto E and Kai M: Epigenetic alteration and microRNA dysregulation in cancer. Front Genet. 4:2582013. View Article : Google Scholar : PubMed/NCBI
3	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
4	Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI
5	Griffiths-Jones S: miRBase: MicroRNA sequences and annotation. Curr Protoc Bioinformatics. Chapter 12, Unit 12. 19:1–10. 2010.
6	Iborra M, Bernuzzi F, Invernizzi P and Danese S: MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response. Autoimmun Rev. 11:305–314. 2012. View Article : Google Scholar
7	Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM and Yin YB: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 16:939–946. 2007. View Article : Google Scholar : PubMed/NCBI
8	Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
9	Neilson JR, Zheng GX, Burge CB and Sharp PA: Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Deve. 21:578–589. 2007. View Article : Google Scholar
10	Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA and Manjunath N: MiRNA profiling of naive, effector and memory CD8 T cells. PloS One. 2:e10202007. View Article : Google Scholar
11	Zhou B, Wang S, Mayr C, Bartel DP and Lodish HF: miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA. 104:7080–7085. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kaplan MM and Gershwin ME: Primary biliary cirrhosis. N Engl J Med. 353:1261–1273. 2005. View Article : Google Scholar : PubMed/NCBI
13	Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, Tsuneyama K, Nakanuma Y, Leung P, Ansari AA, et al: Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology. 53:1270–1281. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hirschfield GM and Gershwin ME: The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 8:303–330. 2013. View Article : Google Scholar : PubMed/NCBI
15	Corpechot C, Chazouillères O and Poupon R: Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol. 55:1361–1367. 2011. View Article : Google Scholar : PubMed/NCBI
16	Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H and Takikawa H: Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 50:675–682. 2015. View Article : Google Scholar
17	Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA and Gershwin ME: Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun. 32:246–253. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
19	Poupon R: Primary biliary cirrhosis: A 2010 update. J Hepatol. 52:745–758. 2010. View Article : Google Scholar : PubMed/NCBI
20	Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O and Poupon R: Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 48:871–877. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ and van Buuren HR; Dutch PBC Study Group: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 136:1281–1287. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pares A, Caballería L and Rodes J: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 130:715–720. 2006. View Article : Google Scholar : PubMed/NCBI
23	Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, Gautheron J, Schneider AT, Koppe C, Kreggenwinkel K, et al: Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 35:1172–1184. 2015. View Article : Google Scholar
24	Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, et al: Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 106:1663–1669. 2011. View Article : Google Scholar : PubMed/NCBI
25	D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, et al: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 31:2765–2773. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Su Y, Xu F, Kong J, Yu H and Qian B: Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PloS One. 8:e814082013. View Article : Google Scholar : PubMed/NCBI
27	Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
28	He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB and Zhang Y: MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 41:498–508. 2013. View Article : Google Scholar :
29	Han K, Zhao T, Chen X, Bian N, Yang T, Ma Q, Cai C, Fan Q, Zhou Y and Ma B: microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol. 45:1437–1449. 2014.PubMed/NCBI
30	Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, et al: miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med. 16:1134–1140. 2010. View Article : Google Scholar : PubMed/NCBI
31	Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
32	Yang L, Ma Z, Wang D, Zhao W, Chen L and Wang G: MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther. 9:803–808. 2010. View Article : Google Scholar : PubMed/NCBI
33	Rukov JL, Wilentzik R, Jaffe I, Vinther J and Shomron N: Pharmaco-miR: Linking microRNAs and drug effects. Brief Bioinform. 15:648–659. 2014. View Article : Google Scholar :